aleabitoreddit 5.0 764 ideas
After 1 day
47%winrate
+0.1% avg
259W / 293L · 552/670 ideas
After 1 week
57%winrate
+3.8% avg
297W / 227L · 524/675 ideas
After 1 month
55%winrate
+3.7% avg
184W / 148L · 332/675 ideas
Recent positions
TickerDirEntryP&LDate
By sector
Stock
616 ideas
+7.1%
ETF
128 ideas
-5.5%
Crypto
9 ideas
-9.6%
unresolved
5 ideas
sector
2 ideas
private
1 ideas
foreign_stock
1 ideas
taiwan-listed stock
1 ideas
equity
1 ideas
Top tickers (by frequency)
AAOI
98 ideas
91% W
+4.7%
IREN
65 ideas
93% W
+4.7%
AXTI
44 ideas
100% W
+45.4%
EWY
34 ideas
11% W
-8.9%
XLU
28 ideas
4% W
-3.0%
Best and worst calls
Best calls
AXTI LONG
+170.6%
A geopolitical event could create a supply shock in the Indium Phosphide (InP) market due to its duopoly production stru...
Feb 19
TSEM LONG
+66.8%
The author has taken a long position in $TSEM, viewing it as a de-risked large player with backlogged capacity and a ben...
Mar 11
Worst calls
INFQ LONG
-45.1%
This new quantum computing IPO is an attractive long as it appears undervalued relative to peers like IONQ and RGTI, off...
Feb 18
CODA LONG
-30.4%
The author identifies CODA as the primary beneficiary of an unstated theme or event, implying outperformance relative to...
Mar 10
HIMS SHORT
-28.0%
The stock faces significant fundamental headwinds from a major lawsuit that jeopardizes its primary growth driver and fi...
Mar 05
Go long HIMS as revenue re-accelerates driven by a new Novo Nordisk partnership, dropped lawsuits, global acquisitions, and a potential short squeeze with over 30% of the float shorted.
HIMS
HIGH
Apr 16, 18:20
Buy ShunSin Technology as it is significantly undervalued compared to LWLG, given its strategic position as Foxconn's optical packaging arm.
6451
HIGH
Apr 16, 17:01
Buy as the newly announced $41M production order from a lead hyperscaler confirms the anticipated volume ramp is officially underway.
AEHR
HIGH
Apr 16, 15:06
Go long ALRIB as it operates in a profitable duopoly for MBE equipment, trades at low forward multiples, and serves as an irreplaceable sub-$1B supplier to major hyperscalers.
ALRIB
HIGH
Apr 16, 08:32
Go long SIVE based on its low $700m valuation as a key laser supplier to JBL and MRVL, with an upcoming NASDAQ listing expected to drive US institutional inflows.
SIVE
HIGH
Apr 16, 08:07
Maintain long exposure to capture further upside, with the upcoming shareholder vote acting as the primary catalyst for continued price appreciation.
AXTI
MED
Apr 16, 07:49
Buy Sivers Semiconductors as recent capital raises de-risk the balance sheet, JBL confirms use of their lasers, and a planned US NASDAQ listing will attract Western institutional capital.
SIVE
HIGH
Apr 16, 07:14
Buy Win Semiconductors due to its critical foundry positioning for the laser mass production supercycle and a new catalyst powering JBL's 1.6T optical transceivers, which the market underappreciates.
3105.TWO
HIGH
Apr 16, 02:02
Buy SIVE as the recent $13M institutional capital raise eliminates balance sheet risks, and the pursuit of a US NASDAQ listing provides further upside catalysts.
SIVE
HIGH
Apr 16, 00:12
Long $SIVE due to high conviction in management execution following a $13.65M institutional capital raise, which is a strong positive signal and is likely earmarked for an upcoming, value-accretive NASDAQ uplisting.
SIVE
HIGH
Apr 16, 00:02
Buy SIVE ahead of its NASDAQ uplisting to capture institutional inflows, supported by its strong $600m valuation as a laser supplier for JBL and MRVL with minimal dilution.
SIVE
HIGH
Apr 15, 23:28
Position long in SIVE ahead of its upcoming NASDAQ listing, which is expected to act as a massive upside catalyst for price appreciation.
SIVE
MED
Apr 15, 23:16
Buy Sivers ahead of its US NASDAQ listing, as the move is likely to attract new US institutional investor demand and could drive a significant revaluation towards a $2B+ market cap.
SIVE
HIGH
Apr 15, 23:10
Go long ALRIB as a picks-and-shovels play on quantum computing R&D capex, benefiting from Microsoft purchases without needing to pick individual machine winners.
ALRIB
HIGH
Apr 15, 22:49
Buy HIMS due to a bullish FDA peptide category shift, a new partnership with Novo Nordisk, high short interest, and global acquisitions, which together should drive revenue re-acceleration and market share capture at ~70-80% gross margins.
HIMS
HIGH
Apr 15, 22:31